l General Information |
Product Name | Risedronic acid |
General description | Risedronate is an aminobisphosphonate derivative of etidronic acid and calcium chanel blocker that inhibits bone resorption and is used for the treatment of Osteoporosis. |
Synonym | (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid; Risedronate; Risedronic acid |
Purity | ≥98%(HPLC) | CAS Number | 105462-24-6 |
Formula | C7H11NO7P2 | Molecular Weight | 283.113 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | Insoluble |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Risedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism and is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Risedronate Sodium is the sodium salt of risedronic acid, a synthetic pyridinyl bisphosphonate. Risedronic acid binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption. |
Application | 1. Bone Density Conservation Agents 2. Calcium Channel Blockers |
l Packaging & Storage |
Packaging | 1g |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
